Fox Business Flash top headlines are here. Check out what’s clicking on FoxBusiness.com.
Regeneron Pharmaceuticals announced on Thursday the start of the first clinical trial of its investigational dual antibody cocktail for the prevention and treatment of COVID-19.
Continue Reading Below
It is called REGN-COV2.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
The program will cover four study areas: hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, uninfected people in groups that are at high-risk of exposure and uninfected people with close exposure to a COVID-19 patient.
WIDESPREAD MASK-WEARING COULD PREVENT CORONAVIRUS SECOND WAVES: STUDY
“We have created a unique anti-viral antibody cocktail with the potential both to prevent and treat infection, and also to preempt viral ‘escape,’ a critical precaution in the midst of an ongoing global pandemic,” said George D. Yancopoulos, co-founder and chief scientific officer of Regeneron. “REGN-COV2 could have a major impact on public health by slowing spread of the virus and providing a needed treatment for those already sick – and could be available much sooner than a vaccine.”
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| REGN | REGENERON PHARMACEUTICALS INC. | 606.59 | -2.00 | -0.33% |
The antibody cocktail approach may work better for elderly and immuno-compromised patients, who don’t always respond well to vaccines, Yancopoulos added.
Regeneron scientists evaluated fully-human antibodies produced by the company’s mice, which have been genetically-modified to have a human immune system, in addition to antibodies isolated from people who have recovered from COVID-19.
CLICK HERE TO READ MORE ON FOX BUSINESS
The company used the same cocktail approach to develop a triple antibody treatment for Ebola that is currently under regulatory review by the Food and Drug Administration.
